Rheumatology 1999; 38: 1130-1137
© 1999 British Society for Rheumatology
The association of socio-economic status, race, psychosocial factors and outcome in patients with systemic lupus erythematosus
Centre for Rheumatology/Bloomsbury Rheumatology Unit, Department of Medicine, University College London, UK,
1 Divisions of Clinical Immunology/Allergy, Clinical Epidemiology, Montreal General Hospital, McGill University, Montreal, Quebec, Canada,
2 Department of Rheumatology, Division of Immunity and Infection, University of Birmingham, Birmingham and
3 Department of Statistical Science, University College London, London, UK
Correspondence to:
N. Sutcliffe, Centre For Rheumatology/Bloomsbury Rheumatology Unit, Arthur Stanley House, 4th floor, 40–50 Tottenham Street, London W1P 9PG, UK.
Objective. To determine the relationship between socio-economic status, race, psychosocial factors and outcome in patients with systemic lupus erythematosus (SLE).
Methods. One hundred and ninety-five patients with SLE were studied at two centres in the UK (London and Birmingham). Information about sociodemographics, income, employment status, social support and satisfaction with care was obtained. Outcomes were assessed by end-organ damage, disease activity and employment status.
Results. Non-Caucasian race, longer disease duration, higher disease activity and lower level of education were associated with more organ damage in SLE. More satisfaction with access to care and interpersonal aspects of care, but less satisfaction with time spent with doctors, were also associated with more damage. Very long disease duration was associated with higher disease activity. Patients with higher disease activity, lower level of education and from the Birmingham centre were more likely not to be working due to their lupus.
Conclusion. Race and socio-economic status, as well as clinical and psychosocial factors, determine outcome in SLE.
KEY WORDS: SLE, Socio-economic status, Race, Psychosocial factors, Organ damage, Disease activity
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  R. CAMPBELL Jr, G. S. COOPER, and G. S. GILKESON The Impact of Systemic Lupus Erythematosus on Employment J Rheumatol, November 1, 2009; 36(11): 2470 - 2475. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Descloux, I. Durieu, P. Cochat, D. Vital-Durand, J. Ninet, N. Fabien, and R. Cimaz Influence of age at disease onset in the outcome of paediatric systemic lupus erythematosus Rheumatology, July 1, 2009; 48(7): 779 - 784. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. A. Chambers, E. Allen, A. Rahman, and D. Isenberg Damage and mortality in a group of British patients with systemic lupus erythematosus followed up for over 10 years Rheumatology, June 1, 2009; 48(6): 673 - 675. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C Gordon, G Bertsias, J P A Ioannidis, J Boletis, S Bombardieri, R Cervera, C Dostal, J Font, I-M Gilboe, F Houssiau, et al. EULAR points to consider for conducting clinical trials in systemic lupus erythematosus Ann Rheum Dis, April 1, 2009; 68(4): 470 - 476. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J Alvarez-Nemegyei and A Bautista-Botello Complementary or alternative therapy use and health status in systemic lupus erythematosus Lupus, February 1, 2009; 18(2): 159 - 163. [Abstract] [PDF]
|
|
|
|
|
|
M Bandeira, S Buratti, M Bartoli, C Gasparini, L Breda, A Pistorio, S Grassi, M. Alpigiani, G Barbano, L. Janz-Junior, et al. Relationship between Damage Accrual, Disease Flares and Cumulative Drug Therapies in Juvenile-Onset Systemic Lupus Erythematosus Lupus, August 1, 2006; 15(8): 515 - 520. [Abstract] [PDF]
|
|
|
|
 |
|
 R. S. Cvetkovski, R. Zachariae, H. Jensen, J. Olsen, J. D. Johansen, and T. Agner Prognosis of Occupational Hand Eczema: A Follow-up Study. Arch Dermatol, March 1, 2006; 142(3): 305 - 311. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A H Seawell and S Danoff-Burg Psychosocial research on systemic lupus erythematosus: a literature review Lupus, December 1, 2004; 13(12): 891 - 899. [Abstract] [PDF]
|
|
|
|
|
|
V Strand Clinical trial design in systemic lupus erythematosus: lessons learned and future directions Lupus, May 1, 2004; 13(5): 406 - 411. [Abstract] [PDF]
|
|
|
|
|
|
A Boonen, D van der Heijde, R Landewe, F Guillemin, M Rutten-van Molken, M Dougados, H Mielants, K de Vlam, H van der Tempel, S Boesen, et al. Direct costs of ankylosing spondylitis and its determinants: an analysis among three European countries Ann Rheum Dis, August 1, 2003; 62(8): 732 - 740. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S Sundaramurthy, T M Bush, C M Neuwelt, and M M Ward Time perspective predicts the progression of permanent organ damage in patients with systemic lupus erythematosus Lupus, June 1, 2003; 12(6): 443 - 448. [Abstract] [PDF]
|
|
|
|
|
|
C.-S. Yee, H. Hussein, J. Skan, S. Bowman, D. Situnayake, and C. Gordon Association of damage with autoantibody profile, age, race, sex and disease duration in systemic lupus erythematosus Rheumatology, February 1, 2003; 42(2): 276 - 279. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y Molad, A Gorshtein, A J Wysenbeek, D Guedj, R Majadla, A Weinberger, and M Amit-Vazina Protective effect of hydroxychloroquine in systemic lupus erythematosus. Prospective long-term study of an Israeli cohort{ Lupus, June 1, 2002; 11(6): 356 - 361. [Abstract] [PDF]
|
|
|
|
|
|
N. Sutcliffe, A. E. Clarke, R. Taylor, C. Frost, and D. A. Isenberg Total costs and predictors of costs in patients with systemic lupus erythematosus Rheumatology, January 1, 2001; 40(1): 37 - 47. [Abstract] [Full Text] [PDF]
|
|